Ernexa Therapeutics Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Ernexa Therapeutics Inc. (ERNA) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $3.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-06
- Ernexa Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $7.29M, a 3758.73% increase year-over-year.
- Ernexa Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $189.00K.
- Ernexa Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$2.46M.
- Ernexa Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$6.05M, a 192.85% decline year-over-year.
- Ernexa Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $155.00K.
- Ernexa Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$9.94M.
- Ernexa Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$3.87M.
- Ernexa Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$1.44M, a 109.40% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.14M 10-Q · filed 2026-08-06 | ||||||
| 2026-03-31 | $7.29M 10-Q · filed 2026-05-11 | ||||||
| 2025-12-31 | $155.00K 10-K · filed 2026-03-13 | ||||||
| 2025-09-30 | $1.32M 10-Q · filed 2025-11-07 | ||||||
| 2025-06-30 | $2.59M 10-Q · filed 2026-08-06 | ||||||
| 2025-03-31 | $189.00K 10-Q · filed 2026-05-11 | ||||||
| 2024-12-31 | -$9.94M 10-K · filed 2026-03-13 | ||||||
| 2024-09-30 | -$7.41M 10-Q · filed 2025-11-07 | ||||||
| 2024-06-30 | -$4.99M 10-Q · filed 2025-08-13 | ||||||
| 2024-03-31 | -$2.46M 10-Q · filed 2025-05-07 | ||||||
| 2023-12-31 | -$3.87M 10-K · filed 2025-03-12 | ||||||
| 2023-09-30 | -$6.89M 10-Q · filed 2024-11-12 | ||||||
| 2023-06-30 | -$9.61M 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | -$6.05M 10-Q · filed 2024-05-14 | ||||||
| 2022-12-31 | -$1.44M 10-K · filed 2024-03-14 | ||||||
| 2022-09-30 | -$3.73M 10-Q · filed 2023-11-13 | ||||||
| 2022-06-30 | $2.42M 10-Q · filed 2023-08-11 | ||||||
| 2022-03-31 | $6.51M 10-Q · filed 2023-05-11 | ||||||
| 2021-12-31 | $15.36M 10-K · filed 2023-03-20 | ||||||
| 2021-09-30 | $22.75M 10-Q · filed 2022-11-14 | $22.75M 10-Q · filed 2021-11-12 | |||||
| 2021-06-30 | $48.53M 10-Q · filed 2022-08-11 | $48.53M 10-Q · filed 2021-08-13 | |||||
| 2021-03-31 | $6.78M 10-Q · filed 2022-07-01 | $6.78M 10-Q · filed 2021-05-17 | |||||
| 2020-12-31 | -$3.47M 10-K/A · filed 2022-07-01 | ||||||
| 2020-09-30 | -$2.05M 10-Q · filed 2021-11-12 | ||||||
| 2020-06-30 | $85.86K 10-Q · filed 2021-08-13 | ||||||
| 2020-03-31 | -$1.57M 10-Q · filed 2021-05-17 | ||||||
| 2019-03-31 | $111.00K 10-Q · filed 2019-05-14 | ||||||
| 2018-12-31 | -$517.00K 10-K · filed 2019-03-22 | ||||||
| 2018-03-31 | -$718.00K 10-Q · filed 2019-05-14 | ||||||
| 2017-12-31 | -$2.37M 10-K · filed 2019-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |